Antibody response in patients admitted to the hospital with suspected SARS-CoV-2 infection: results from a multicenter study across Spain

Aim To evaluate the serological response against SARS-CoV-2 in a multicenter study representative of the Spanish COVID pandemic. Methods IgG and IgM + IgA responses were measured on 1466 samples from 1236 Spanish COVID-19 patients admitted to the hospital, two commercial ELISA kits (Vircell SL, Spai...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of clinical microbiology & infectious diseases 2021-06, Vol.40 (6), p.1343-1349
Hauptverfasser: Fuentes, Ana, Serrano-Conde, Esther, Roldán, Carolina, Benito-Ruesca, Rafael, Mejías, Gregoria, Sampedro, Antonio, March-Roselló, Gabriel, Fernández-Natal, Isabel, Esperalba, Juliana, Rodríguez, Mario José, Martínez de Aguirre, Paula, Salas, Carlos, Roc, María Lourdes, Soria, Luis Miguel, Parra-Grande, Mónica, Montero, María Dolores, Fernández-Roblas, Ricardo, Franco-Álvarez de Luna, Francisco, Lozano, Carmen, García, Federico
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aim To evaluate the serological response against SARS-CoV-2 in a multicenter study representative of the Spanish COVID pandemic. Methods IgG and IgM + IgA responses were measured on 1466 samples from 1236 Spanish COVID-19 patients admitted to the hospital, two commercial ELISA kits (Vircell SL, Spain) based on the detection of antibodies against the viral spike protein and nucleoprotein, were used. Results Approximately half of the patients presented antibodies (56.8% were IgM + IgA positive and 43.0% were IgG positive) as soon as 2 days after the first positive PCR result. Serological test positivity increased with time from the PCR test, and 10 days after the first PCR result, 91.5% and 88.0% of the patients presented IgM + IgA and IgG antibodies, respectively. Conclusion The high values of sensitivity attained in the present study from a relatively early period of time after hospitalization support the use of the evaluated serological assays as supplementary diagnostic tests for the clinical management of COVID-19.
ISSN:0934-9723
1435-4373
1435-4373
DOI:10.1007/s10096-020-04139-5